Beijing's CANbridge Raises $25 Million for Immuno-Oncology Drugs

CANbridge Life Sciences of Beijing completed a $25 million Series B round from China investors. The company, which has raised $40 million to date, said it expects to announce additional strategic transactions this year. CANbridge will use the money to fund clinical trials of its two lead candidates, both of which are oncology drugs. CANbridge focuses on developing Western drug candidates in China and North Asia. Lapam Capital, a Beijing life science VC, led the round and was joined by other China life science investors. More details.... Share this with colleagues: // //